1,047 reports of this reaction
2.3% of all ALENDRONATE SODIUM TABLET reports
#9 most reported adverse reaction
DYSPNOEA is the #9 most commonly reported adverse reaction for ALENDRONATE SODIUM TABLET, manufactured by Marlex Pharmaceuticals, Inc.. There are 1,047 FDA adverse event reports linking ALENDRONATE SODIUM TABLET to DYSPNOEA. This represents approximately 2.3% of all 45,629 adverse event reports for this drug.
Patients taking ALENDRONATE SODIUM TABLET who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for ALENDRONATE SODIUM TABLET, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for ALENDRONATE SODIUM TABLET:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,047 FDA reports for ALENDRONATE SODIUM TABLET. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.3% of all adverse event reports for ALENDRONATE SODIUM TABLET, making it a notable side effect.
If you experience dyspnoea while taking ALENDRONATE SODIUM TABLET, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.